Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Bile Ducts, Intrahepatic: Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.Adenoma, Bile Duct: A benign tumor of the intrahepatic bile ducts.Klatskin's Tumor: Adenocarcinoma of the common hepatic duct bifurcation. These tumors are generally small, sharply localized, and seldom metastasizing. G. Klatskin's original review of 13 cases was published in 1965. Once thought to be relatively uncommon, tumors of the bifurcation of the bile duct now appear to comprise more than one-half of all bile duct cancers. (From Holland et al., Cancer Medicine, 3d ed, p1457)Bile Ducts, Extrahepatic: Passages external to the liver for the conveyance of bile. These include the COMMON BILE DUCT and the common hepatic duct (HEPATIC DUCT, COMMON).Opisthorchis: A genus of trematode liver flukes of the family Opisthorchidae. It consists of the following species: O. felineus, O. noverca (Amphimerus noverca), and O. viverrini. The intermediate hosts are snails, fish, and AMPHIBIANS.Opisthorchiasis: Infection with flukes of the genus Opisthorchis.Biliary Tract Surgical Procedures: Any surgical procedure performed on the biliary tract.Hepatic Duct, Common: Predominantly extrahepatic bile duct which is formed by the junction of the right and left hepatic ducts, which are predominantly intrahepatic, and, in turn, joins the cystic duct to form the common bile duct.Cholangitis, Sclerosing: Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.Liver Neoplasms: Tumors or cancer of the LIVER.Hepatectomy: Excision of all or part of the liver. (Dorland, 28th ed)Lithiasis: A condition characterized by the formation of CALCULI and concretions in the hollow organs or ducts of the body. They occur most often in the gallbladder, kidney, and lower urinary tract.Clonorchiasis: Infection of the biliary passages with CLONORCHIS SINENSIS, also called Opisthorchis sinensis. It may lead to inflammation of the biliary tract, proliferation of biliary epithelium, progressive portal fibrosis, and sometimes bile duct carcinoma. Extension to the liver may lead to fatty changes and cirrhosis. (From Dorland, 27th ed)Fascioliasis: Liver disease caused by infections with parasitic flukes of the genus FASCIOLA, such as FASCIOLA HEPATICA.Bile Ducts: The channels that collect and transport the bile secretion from the BILE CANALICULI, the smallest branch of the BILIARY TRACT in the LIVER, through the bile ductules, the bile ducts out the liver, and to the GALLBLADDER for storage.Fasciola hepatica: A species of helminth commonly called the sheep liver fluke. It occurs in the biliary passages, liver, and gallbladder during various stages of development. Snails and aquatic vegetation are the intermediate hosts. Occasionally seen in man, it is most common in sheep and cattle.Clonorchis sinensis: A species of trematode flukes of the family Opisthorchidae. Many authorities consider this genus belonging to Opisthorchis. It is common in China and other Asiatic countries. Snails and fish are the intermediate hosts.Thailand: Formerly known as Siam, this is a Southeast Asian nation at the center of the Indochina peninsula. Bangkok is the capital city.Cholangiopancreatography, Endoscopic Retrograde: Fiberoptic endoscopy designed for duodenal observation and cannulation of VATER'S AMPULLA, in order to visualize the pancreatic and biliary duct system by retrograde injection of contrast media. Endoscopic (Vater) papillotomy (SPHINCTEROTOMY, ENDOSCOPIC) may be performed during this procedure.Gallbladder Neoplasms: Tumors or cancer of the gallbladder.Jaundice, Obstructive: Jaundice, the condition with yellowish staining of the skin and mucous membranes, that is due to impaired BILE flow in the BILIARY TRACT, such as INTRAHEPATIC CHOLESTASIS, or EXTRAHEPATIC CHOLESTASIS.Cholangitis: Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.Biliary Tract Neoplasms: Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.Cell Line, Tumor: A cell line derived from cultured tumor cells.CA-19-9 Antigen: Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.Drainage: The removal of fluids or discharges from the body, such as from a wound, sore, or cavity.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.Cholangiopancreatography, Magnetic Resonance: Non-invasive diagnostic technique for visualizing the PANCREATIC DUCTS and BILE DUCTS without the use of injected CONTRAST MEDIA or x-ray. MRI scans provide excellent sensitivity for duct dilatation, biliary stricture, and intraductal abnormalities.Thioacetamide: A crystalline compound used as a laboratory reagent in place of HYDROGEN SULFIDE. It is a potent hepatocarcinogen.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Iridium Radioisotopes: Unstable isotopes of iridium that decay or disintegrate emitting radiation. Ir atoms with atomic weights 182-190, 192, and 194-198 are radioactive iridium isotopes.Cholangiography: An imaging test of the BILIARY TRACT in which a contrast dye (RADIOPAQUE MEDIA) is injected into the BILE DUCT and x-ray pictures are taken.Food Parasitology: The presence of parasites in food and food products. For the presence of bacteria, viruses, and fungi in food, FOOD MICROBIOLOGY is available.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Choledochal Cyst: A congenital anatomic malformation of a bile duct, including cystic dilatation of the extrahepatic bile duct or the large intrahepatic bile duct. Classification is based on the site and type of dilatation. Type I is most common.Portal Vein: A short thick vein formed by union of the superior mesenteric vein and the splenic vein.Liver Transplantation: The transference of a part of or an entire liver from one human or animal to another.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Terminology as Topic: The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.Gallbladder Diseases: Diseases of the GALLBLADDER. They generally involve the impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, neoplasms, or other diseases.Gallbladder: A storage reservoir for BILE secretion. Gallbladder allows the delivery of bile acids at a high concentration and in a controlled manner, via the CYSTIC DUCT to the DUODENUM, for degradation of dietary lipid.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Jaundice: A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.PubMed: A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.BooksPublishing: "The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.

Lobar decrease in 99mTc-GSA accumulation in hilar cholangiocarcinoma. (1/1040)

Hilar cholangiocarcinoma can obstruct hepatic ducts and involve the portal veins. Both biliary stasis and decrease in portal venous flow are known to reduce 99mTc-diethylenetriamine pentaacetic acid-galactosyl human serum albumin (GSA) accumulation. The specific relationship between these pathological conditions due to hilar cholangiocarcinomas and 99mTc-GSA accumulation has never been clarified. METHODS: Sixteen patients with hilar cholangiocarcinomas who underwent 99mTc-GSA liver scintigraphy were reviewed. The relationship between significant decrease in 99mTc-GSA accumulation and lobar biliary stasis, or decrease in the portal venous flow, was evaluated. Average counts of region of interest placed in both right and left lobes were compared in the same transaxial SPECT section. Count ratios of right and left lobes were calculated. RESULTS: Significant lobar decrease in 99mTc-GSA accumulation was observed in 6 of the 16 patients. Ipsilateral portal venous stenosis or obstruction was seen in all these 6 patients, whereas ipsilateral portal venous stenosis or obstruction was seen in only 1 of the other 10 patients. Symmetric bile duct dilatation was seen in 13 patients, and asymmetric bile duct dilatation was seen in 3. Lobar decrease in 99mTc-GSA accumulation correlated well with decrease in ipsilateral portal venous flow (P < 0.0005). The count ratio was significantly reduced when unilateral portal venous flow decreased (P < 0.05). CONCLUSION: Using 99mTc-GSA liver scintigraphy, we can predict lobar decrease in ipsilateral portal venous flow and monitor hepatic functional lateralities in patients with hilar cholangiocarcinomas.  (+info)

Binding of tumour necrosis factor-alpha (TNF-alpha) to TNF-RI induces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines. (2/1040)

Cholangiocarcinoma (CCA), a tumour of the bile duct epithelium, occurs with a higher incidence in South-east Asian countries than in Europe and North America. The prognosis is poor, due to the unavailability of early diagnosis and the tumours being relatively resistant to chemotherapy. In the present study one of the fatal routes of this tumour was studied. This death was stimulated by TNF-alpha. TNF-alpha at a concentration of 760 pg/ml and 100 pg/ml in the presence of 1 microgram/ml actinomycin D induced 50% cell death of the two established human cholangiocarcinoma cell lines HuCCA-1 and HuCCA-INu, respectively. Preincubation of both cell lines with MoAb to TNF-RI or TNF-RII before TNF-alpha treatment showed that only the MoAb specific to TNF-RI inhibited death. The death of these two cell lines was proved to be apoptosis. Western blot analysis of extracts from both cell lines demonstrated a cleavage of poly (ADP-ribose) polymerase (PARP) within 6-8 h following TNF-alpha treatment. The degradation of PARP was prevented by a MoAb to TNF-RI indicating that the TNF-RI but not TNF-RII was involved in TNF-induced apoptosis in these two human cholangiocarcinoma cell lines. Moreover, peptide inhibitor for caspase II subfamily, Ac-DEVD-CHO, reduced the cytolysis of TNF-alpha-treated cholangiocarcinoma cells. The inhibitor also prevented degradation of PARP. These results indicate that the interaction between TNF-alpha and TNF-RI alone generated a sufficient signal to activate a caspase II subfamily-dependent apoptosis in human cholangiocarcinoma cell lines.  (+info)

Lymph node metastasis in intrahepatic cholangiocarcinoma. (3/1040)

BACKGROUND: Lymph node metastasis is a significant prognostic factor in intrahepatic cholangiocarcinoma. This study was aimed at investigating lymph node metastasis in intrahepatic cholangiocarcinoma and to examine whether the extent of metastasis affects outcomes after surgery. METHODS: From 1980 through 1996, 70 patients with intrahepatic cholangiocarcinoma underwent hepatectomy, with a 50% curative resection rate. Lymph node dissection was performed in 51 patients, and the presence of lymph node metastasis was examined microscopically. The metastatic nodes were divided into groups N1, N2 or N3 using the classification proposed by the Liver Cancer Study Group of Japan. RESULTS: Twenty-three patients had lymph node metastasis. Metastasis was to N1 nodes in 10 patients, to N2 nodes in nine patients and to N3 nodes in four patients. Nineteen patients had metastatic nodes in the hepatoduodenal ligament, which was the most common metastatic site regardless of tumor location. The five-year survival rate in patients with lymph node metastasis (0%) was significantly lower (p < 0.0001) than that in patients without lymph node metastasis (51 %); however, five-year survival rates did not differ between patients with metastases to N1, N2 and N3 nodes. CONCLUSIONS: Lymph nodes in the hepatoduodenal ligament may be sentinel nodes for intrahepatic cholangiocarcinoma, and outcomes after surgery for patients with lymph node metastasis are poor regardless of the sites of nodal metastasis.  (+info)

Promoting effects of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone on rat glandular stomach carcinogenesis initiated with N-methyl-N'-nitro-N-nitrosoguanidine. (4/1040)

The modifying effects of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX), a mutagenic by-product in chlorinated water, on the development of glandular stomach cancers were investigated in Wistar rats. A total of 120 males, 6 weeks of age, were divided into six groups. After initiation with 100 ppm N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) solution and 5% NaCl diet for 8 weeks, 30 rats each in groups 1-3 were given MX in the drinking water at concentrations of 30, 10, or 0 ppm for the following 57 weeks. Ten animals each in groups 4-6 were administered the MX without prior carcinogen exposure. There were no statistical significant differences in final body weights between the groups. The incidences and multiplicities of adenocarcinomas in the glandular stomachs were significantly higher (P < 0.05) in the initiated 30 ppm MX group than those in the MNNG/NaCl group. The incidences of atypical hyperplasias in the glandular stomachs were also significantly increased (P < 0.05 or 0.01) by the MX treatments. With their multiplicity, the effects were clearly dose dependent. Interestingly, the 30 ppm MX alone itself induced atypical hyperplasias in the pylorus, although the incidences and severity were low. Moreover, MX showed a tendency to enhance the development of intrahepatic cholangiocellular tumors and thyroid follicular cell tumors in the MNNG-treated animals. The results of the present study thus indicate that MX exerts promoting effects when given during the postinitiation phase of two-stage glandular stomach carcinogenesis in rats.  (+info)

Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. (5/1040)

p73, the first homologue of the tumour suppressor protein p53, was recently discovered on chromosome 1p36 and has been shown to induce apoptosis in a p53-like manner. The present study was performed with the aim of investigating the expression of p53, its new homologue p73 and the occurrence of apoptosis in cholangiocellular carcinoma. Protein levels of p73 were examined in 41 patients with curatively (R0-) resected cholangiocellular carcinomas with an antiserum, raised against a peptide in the N-terminal domain of p73. The incidence of mutations in the p53 gene was analysed by direct sequencing and also immunohistochemically. Apoptotic cell death was assessed using in-situ end-labelling (ISEL) technique in combination with morphological criteria. The results obtained were correlated with patient survival. Immunostaining of p73 protein was detected in 17/41 carcinomas examined (41%). The immunoreactivity was confined to the cell nucleus. In 15/41 patients (37%), mutations of the p53 gene were observed. Eleven out of these 15 patients stained also positive for p73. In contrast, out of 26 patients without any detectable p53 mutation, only six exhibited p73 immunostaining. We failed to observe a correlation between p73 expression or p53 and apoptosis within a given tumour. Survival analysis including the parameters stage and grade of disease, p73 and p53, and also apoptosis, showed that tumour stage and grade as well as p53 and p73 were significantly related to prognosis. In Cox regression survival analysis, however, only extent of primary tumour and lymph node status had an independent prognostic impact. Our results with a high prevalence of p73 within tumours harbouring mutated p53 gene suggest that p73 could compensate for p53 function. We failed to establish p73 or p53 as independent prognostic factors in cholangiocellular carcinoma of the liver.  (+info)

Intrahepatic peripheral cholangiocarcinoma: CT features in 18 pathologically proven cases. (6/1040)

OBJECTIVE: To determine the morphological features of 18 pathologically proven intrahepatic peripheral cholangiocarcinoma (IHPCC) cases in computerized tomography (CT) image. METHODS: All 18 patients had CT, using Picker I.Q.T/C and taking pre-contrast continuous 10-mm sections throughout the liver and post-contrast continuous 10-mm sections throughout the focuses. RESULTS: The disease was characterized in CT image by the following: all focuses were found in the periphery of the liver and shown as a lobulated or fused hypodense space-occupying mass; there were one or more divergent or confluent, circular or irregular cystic areas with much lower density, in the majority. All focuses could be enhanced slightly and most revealed a dim edge. Dilated bile ducts around the focus were found frequently; the dilated bile ducts especially seemed to encircle the focus (33.3%, 6/18). This phenomenon were referred to as "encysted sign of dilated bile ducts". CONCLUSIONS: CT scanning should be one of the most important investigative methods for IHPCC due to the disease characteristics identified in CT image, especially "encysted sign of dilated bile ducts" which possesses specificity in diagnosing the disease.  (+info)

Apoptosis and tumorigenesis in human cholangiocarcinoma cells. Involvement of Fas/APO-1 (CD95) and calmodulin. (7/1040)

We have previously demonstrated that tamoxifen inhibits the growth of human cholangiocarcinoma cells in culture and inhibits tumor growth when cells are injected into nude mice. However, the mechanism of action of tamoxifen remains unknown. Here we demonstrate that tamoxifen and trifluoperazine, both potent calmodulin antagonists, induce apoptosis in vitro, probably acting via the Fas system, in human cholangiocarcinoma cells. Human cholangiocarcinoma cell lines heterogeneously express Fas antigen on their surface. Fas-negative and Fas-positive surface-expressing cells were isolated, cloned, and cultured. Fas antibody, tamoxifen, and trifluoperazine induced dose-dependent apoptosis only in Fas-positive cells; Fas-negative cells were unaffected. Furthermore, apoptosis induced by tamoxifen in Fas-positive cells was blocked by an inhibitory Fas antibody. Tamoxifen was not acting through an anti-estrogenic mechanism, because neither Fas-negative nor Fas-positive cells expressed estrogen receptors and the pure anti-estrogen compound, ICI 182780, did not induce apoptosis in either cell line. Fas-negative cells, but not Fas-positive cells, were able to produce tumors when subcutaneously injected into nude mice. These findings suggest Fas may be a candidate oncogene involved in the pathogenesis of cholangiocarcinoma. Furthermore, the similarity between the pro-apoptotic effects of tamoxifen and trifluoperazine support an underlying molecular mechanism for Fas-mediated apoptosis that involves calmodulin.  (+info)

Recurrent thrombo-embolic episodes: the association of cholangiocarcinoma with antiphospholipid syndrome. (8/1040)

Antiphospholipid syndrome is a disorder of recurrent vascular thrombosis, pregnancy loss and thrombocytopenia associated with persistently elevated levels of antiphospholipid antibodies. It was first described in a group of patients with systemic lupus erythematosus but has since been associated with a wide range of conditions, including other autoimmune disorders and malignancy. It can also occur in isolation, the so-called primary antiphospholipid syndrome. We describe an elderly woman with the antiphospholipid syndrome thought to be associated with a cholangiocarcinoma.  (+info)

TY - JOUR. T1 - Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma. T2 - Outcome after liver transplantation. AU - Maganty, Kishore. AU - Levi, David. AU - Moon, Jang. AU - Bejarano, Pablo A.. AU - Arosemena, Leopoldo. AU - Tzakis, Andreas. AU - Martin, Paul. PY - 2010/12/1. Y1 - 2010/12/1. N2 - Background: Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma is a rare hepatobiliary malignancy incorporating components derived from both hepatocyte and intrahepatic bile duct epithelium. The natural history, treatment, and prognosis of this distinct cancer differ from hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) and are not completely understood. There is considerable controversy about the classification, treatment, and survival, which in turn is related to the rarity of the condition. Treatment options include surgical resection and the prognosis is believed to be better than CC but worse than HCC alone. Methods: We report a single-center liver ...
The original observations of this study relate to inflammation, NO production, DNA damage, and inhibition of DNA repair as related mechanisms for the development and/or progression of cholangiocarcinoma. Our results directly demonstrate the following: (a) human cholangiocarcinomas express the iNOS protein; (b) proinflammatory cytokines stimulate iNOS message and protein expression and the production of NO in cholangiocarcinoma cell lines; (c) the magnitude of NO produced is sufficient to cause single-stranded, double-stranded, and oxidative DNA lesions in the malignant cell lines; and (d) stimulated NO generation is associated with impaired global DNA repair activity in the cholangiocarcinoma cell lines. These data suggest that NO generated in response to inflammation may initiate malignant transformation of biliary epithelia and/or promote progression of established cholangiocarcinoma. Each of these observations is discussed in greater detail below.. iNOS expression with NO generation has been ...
Slug is an E-cadherin repressor and a suppressor of PUMA (p53 upregulated modulator of apoptosis) and it has recently been demonstrated that Slug plays an important role in controlling apoptosis. In this study, we examined whether Slugs ability to silence expression suppresses the growth of cholangiocarcinoma cells and/or sensitizes cholangiocarcinoma cells to chemotherapeutic agents through induction of apoptosis. We targeted the Slug gene using siRNA (Slug siRNA) via full Slug cDNA plasmid (Slug cDNA) transfection of cholangiocarcinoma cells. Slug siRNA, cisplatin, or Slug siRNA in combination with cisplatin, were used to treat cholangiocarcinoma cells in vitro. Western blot was used to detect the expression of Slug, PUMA, and E-cadherin protein. TUNEL, Annexin V Staining, and cell cycle analysis were used to detect apoptosis. A nude mice subcutaneous xenograft model of QBC939 cells was used to assess the effect of Slug silencing and/or cisplatin on tumor growth. Immunohistochemical staining was used
Lymphoepithelioma-like carcinoma (LELC) of the liver is extremely rare. To our knowledge, only 16 cases of pure LELC or LELC with ordinary adenocarcinoma arising in the hepatobiliary tract have been reported in the English literature.1-7 Most of these tumours (68%, 11/16) were positive for Epstein-Barr virus (EBV) by EBV-encoded small non-polyadenylated RNA (EBER-1) in situ hybridisation.1-6 However, association of intrahepatic cholangiocarcinoma bearing an intense lymphoplasmacytic infiltration with EBV infection has not been reported. We were the first to present two cases of intrahepatic cholangiocarcinoma with dense lymphoplasmacytic infiltration from Southern China, an area that is well known for and has a high-incidence of nasopharyngeal carcinoma, showing EBV infection, but one case of LELC was associated with EBV infection as well. ...
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage ...
TY - JOUR. T1 - The impact of portal vein resection on outcomes for hilar cholangiocarcinoma. T2 - A multi-institutional analysis of 305 cases. AU - De Jong, Mechteld C.. AU - Marques, Hugo. AU - Clary, Bryan M.. AU - Bauer, Todd W.. AU - Marsh, J. Wallis. AU - Ribero, Dario. AU - Majno, Pietro. AU - Hatzaras, Ioannis. AU - Walters, Dustin M.. AU - Barbas, Andrew S.. AU - Mega, Raquel. AU - Schulick, Richard D.. AU - Choti, Michael A.. AU - Geller, David A.. AU - Barroso, Eduardo. AU - Mentha, Gilles. AU - Capussotti, Lorenzo. AU - Pawlik, Timothy M.. PY - 2012/10/1. Y1 - 2012/10/1. N2 - BACKGROUND. Surgical strategy for hilar cholangiocarcinoma often includes hepatectomy, but the role of portal vein resection (PVR) remains controversial. In this study, the authors sought to identify factors associated with outcome after surgical management of hilar cholangiocarcinoma and examined the impact of PVR on survival. METHODS: Three hundred five patients who underwent curative-intent surgery for hilar ...
Cholangiocarcinomas are a heterogeneous group of malignancies arising from a number of cells of origin along the biliary tree. Although most cases in Western countries are sporadic, large population-based studies have identified a number of risk factors. This review summarises the evidence behind reported risk factors and current understanding of the molecular pathogenesis of cholangiocarcinoma, with a focus on inflammation and cholestasis as the driving forces in cholangiocarcinoma development. Cholestatic liver diseases (e.g. primary sclerosing cholangitis and fibropolycystic liver diseases), liver cirrhosis, and biliary stone disease all increase the risk of cholangiocarcinoma. Certain bacterial, viral or parasitic infections such as hepatitis B and C and liver flukes also increase cholangiocarcinoma risk. Other risk factors include inflammatory disorders (such as inflammatory bowel disease and chronic pancreatitis), toxins (e.g. alcohol and tobacco), metabolic conditions (diabetes, obesity and non
Forest plot of extrahepatic cholangiocarcinoma risk associated with HCV infection. The pooled risk estimate was 1.75 (95% CI, 1.00 to 3.051).
Surgical resection remains the mainstay of curative treatment for intrahepatic cholangiocarcinoma (ICC). Prognosis after surgery is unsatisfactory despite improvements in treatment and post-operative clinical management. Despite developments in the molecular profiling of ICC, the preoperative prediction of prognosis remains a challenge. This study aimed to identify clinical prognostic indicators by investigating the molecular profiles of ICC and evaluating the preoperative imaging data of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET). A retrospective analysis was performed on 50 consecutive patients with ICC who underwent curative hepatectomy after 18F-FDG-PET examination. To evaluate the molecular profiles of ICC, KRAS mutation status was assessed in resected specimens. For the assessment of glucose uptake, we observed the expression of glucose transporter-1 (GLUT-1) by immunohistochemistry. The data of 18F-FDG-PET were re-evaluated as follows: maximum standardized uptake value,
Few studies have evaluated the risk of cancers other than hepatocellular carcinoma associated with hepatitis B virus (HBV) infection. This study aimed to estimate incidence rates of intrahepatic cholangiocarcinoma (ICC) and non-Hodgkin lymphoma (NHL) and its major subtypes in a nationwide cohort of parous women and to assess their associations with chronic HBV infection. We conducted a cohort study including 1,782,401 pregnant Taiwanese women whose HBV serostatus was obtained from the National Hepatitis B Vaccination Registry. Newly diagnosed ICCs and NHLs were ascertained through data linkage with the National Cancer Registry. Risks of ICC and NHL were assessed using Cox proportional hazards regression models. After a mean of 6.91 years of follow-up, there were 18 cases of ICC and 192 cases of NHL, including 99 cases of diffuse large B-cell lymphoma (DLBCL). Incidence rates of ICC were 0.09 and 0.43 per 100,000 person-years, respectively, among women who were hepatitis B surface antigen ...
Intrahepatic cholangiocarcinoma (ICC) is an aggressive, highly lethal tumors and lacks of effective chemo and targeted therapies. Cell lines and animal models, even partially reflecting tumor characteristics, have limits to study ICC biology and drug response. In this work, we created and characterized a novel ICC patient-derived xenograft (PDX) model of Italian origin. Seventeen primary ICC tumors derived from Italian patients were implanted into NOD (Non-Obese Diabetic)/Shi-SCID (severe combined immunodeficient) mice. To verify if the original tumor characteristics were maintained in PDX, immunohistochemical (cytokeratin 7, 17, 19, and epithelial membrane antigen) molecular (gene and microRNA expression profiling) and genetic analyses (comparative genomic hybridization array, and mutational analysis of the kinase domain of EGFR coding sequence, from exons 18 to 21, exons 2 to 4 of K-RAS, exons 2 to 4 of N-RAS, exons 9 and 20 of PI3KCA, and exon 15 of B-RAF) were performed after tumor stabilization.
The aim of this study was to compare the enhancement pattern of intrahepatic cholangiocarcinoma (ICC) on contrast-enhanced ultrasound (CEUS) with that on contrast-enhanced computed tomography (CECT). 40 pathologically proven ICC lesions in 40 patients were evaluated retrospectively with both CEUS and CECT. The enhancement level and pattern in the dynamic phases on both CEUS and CECT were analysed. The diagnostic results of CEUS and CECT before pathological examination were also recorded. During arterial phases, the number of lesions that appeared as (i) peripheral irregular rim-like hyperenhancement, (ii) diffuse heterogeneous hyperenhancement, (iii) diffuse homogeneous hyperenhancement and (iv) diffuse heterogeneous hypoenhancement were 19 (47.5%), 9 (22.5%), 5 (12.5%) and 7 (17.5%), respectively, on CEUS, and 22 (55.0%), 3 (7.5%), 2 (5.0%) and 13 (32.5%), respectively, on CECT (p = 0.125). In the portal phase, the number of lesions showing hyperenhancement and hypoenhancement were 1 (2.5%) and ...
The purpose of this project is to evaluate the role of gadoxetate (Eovist) enhanced dual-energy CT in better evaluating perihilar cholangiocarcinoma, by exploiting the combination of the physiologic behavior of gadoxetate in liver tissue combined with the advantageous mass attenuation coefficient of Gadolinium achievable through dual energy technique. This combination of unique CT imaging sensitivity, high resolution and differential enhancement potentially allows improved visualization and detection of tumor relative to enhancing surrounding hepatic parenchyma and ductal anatomy in the hepatobiliary phase, due to the biliary excretion of the agent.. Cholangiocarcinoma is a hepatic adenocarcinoma that arises from the bile duct epithelium and is the second most prevalent liver cancer after hepatocellular carcinoma. The hilar intrahepatic variety of cholangiocarcinoma can present as an infiltrative, exophytic, or polypoid lesion. Most extra-hepatic cholangiocarcinomas are infiltrative, causing a ...
OBJECTIVES: Hepatocellular carcinoma and cholangiocarcinoma form the majority of primary hepatic tumours and are the third most common cause of cancer-related deaths. These liver tumours rapidly outgrow their vascular supply and become hypoxic, resulting in the production of hypoxia inducible factors and triggering the angiogenic switch. Therefore, inhibiting angiogenesis has proven to be a valuable therapeutic strategy in hepatocellular carcinoma, yet less is known about its use in cholangiocarcinoma. In this study, we assess whether inhibiting the placental growth factor (PlGF) could offer a therapeutic option in mice with hepatocellular carcinoma and cholangiocarcinoma. PlGF is a homologue of the vascular endothelial growth factor, which is only involved in pathological angiogenesis, therefore, its inhibition does not induce adverse effects. METHODS: We have used a chemically induced transgenic mouse model in which both hepatocellular carcinoma and cholangiocarcinoma develop after 25 weeks ...
Background and Aims: It is a challenge to collect samples from bile duct strictures to diagnose patients with cholangiocarcinoma. We investigated the utility of the Spyglass Spyscope, a single-operator endoscope that is used to perform cholangiopancreatoscopy, to identify extrahepatic cholangiocarcinoma in patients who were not diagnosed with this disorder by endoscopic retrograde cholangiopancreatography (ERCP) cytology or endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) analyses. Methods: We conducted a retrospective analysis of data from 30 patients (median age, 67 years; 67percent male) with indeterminate extrahepatic biliary strictures who were ultimately diagnosed with cholangiocarcinoma but had inconclusive results from initial biliary ductal brush cytology and EUS-FNA analyses. Patients then underwent cholangioscopy by using the Spyglass Spyscope and intraductal biopsy analysis. None of the patients had a definitive mass in abdominal imaging or EUS analyses. Results: The ...
Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: A case-control study in Korea
TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells Novel cancer therapy;TRAIL/Apo2L;non-conventional anti-cancer therapy;apoptosis; In the past decade, the incidence and mortality rates of cholangiocarcinoma (CCA) have been increasing worldwide. The relatively low responsiveness of CCA to conventional chemotherapy leads to poor overall survival. Recently, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or Apo2L) has emerged as the most promising anti-cancer therapeutic agent since it is able to selectively induce apoptosis of tumor cells but not normal cells. In this study, we aimed to investigate the therapeutic effect of TRAIL in CCA cell lines (M213, M214 and KKU100) compared with the immortal biliary cell line, MMNK1, either alone or in combination with a subtoxic dose of 5-fluorouracil (5-FU). We found that recombinant human TRAIL (rhTRAIL) was a potential agent which significantly inhibited cell
TY - JOUR. T1 - Tumor necrosis factor-α modulates epithelial mesenchymal transition mediators ZEB2 and S100A4 to promote cholangiocarcinoma progression. AU - Techasen, Anchalee. AU - Namwat, Nisana. AU - Loilome, Watcharin. AU - Duangkumpha, Kassaporn. AU - Puapairoj, Anucha. AU - Saya, Hideyuki. AU - Yongvanit, Puangrat. PY - 2014/9. Y1 - 2014/9. N2 - Background The epithelial-mesenchymal transition (EMT) process strongly contributes to cancer metastasis. This study was to investigate the alteration of EMT-related proteins (ZEB1, ZEB2 and S100A4) in cholangiocarcinoma (CCA) tissues. The effect of tumor necrosis factor-α (TNF-α) on the expression of those molecules in CCA cells was investigated. Methods The quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay was used to quantify ZEB1, ZEB2 and S100A4 mRNA levels in 50 CCA tissues and related its expression to clinicopathological data. ZEB2 protein immunostaining was investigated in 165 CCA tissues. The effect of ...
ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that it is an Oak sponsor of the Cholangiocarcinoma Foundation Annual Conference 2018 in Salt Lake City, Utah.. The conference is organised by the Cholangiocarcinoma Foundation and will be held from 31 January to 2 February 2018. Bringing together researchers, healthcare professionals, policymakers, patients and their caregivers, the conference encourages the engagement of the medical and research communities on cholangiocarcinoma by providing a forum for knowledge and innovation exchange.. For more information, please refer to the English or Chinese press release.. ...
Postoperative Mortality after Liver Resection for Perihilar Cholangiocarcinoma: Development of a Risk Score and Importance of Biliary Drainage of the Future Liver Remnant.
BACKGROUND Surgery is the only curative therapy for patients with hilar cholangiocarcinoma (HCCA). Combined portal vein resection (PVR) could achieve negative resection margins in HCCA patients with portal vein invasion. This systematic review aimed to analysis the efficiency of combined PVR for HCCA. METHODS MEDLINE, EMBASE, the Cochrane Library, the Chinese National Knowledge Infrastructure database, and clinical trial registries were searched through April 2015. Risk ratios (RRs), and 95% confidence intervals (CIs) were calculated. RESULTS The analysis included 21 retrospective studies, altogether involving 2403 patients (patients with PVR, n=637; patients without PVR, n=1766). Patients with PVR were likely to have more advanced HCCA (lymphatic invasion: RR=1.14, 95% CI 1.02 to 1.28; perineural invasion: RR=1.31, 95% CI 1.05 to 1.63) and suffered less curative resections (RR=0.89, 95% CI 0.75 to 0.99). Postoperative morbidity was similar between patients with or without PVR (RR=1.06, 95% CI 0.94
In the west, the exact cause of cholangiocarcinoma is unclear. It is likely that this cancer arises due to a combination of factors, including other illnesses that cause chronic damage to the liver and/or bile ducts, certain toxins and possibly a small genetic predisposition, although it is not believed to be a directly inherited disease. Although most cases of cholangiocarcinoma are in people over 60 years of age, it appears to be increasing across all age groups including younger people. The cause of this ongoing rise is currently unknown.. In Southeast Asia, especially Thailand, which has the worlds highest incidence of cholangiocarcinoma, associated risk factors include eating raw fish infected with liver fluke and chronic typhoid, neither of which occurs in the western world.. ...
Cholangiocarcinoma is a relatively rare disease. In Denmark approximately 150 patients are diagnosed each year. A small part of the patients can be offered surgery, but the operation will rarely be radical, and most patients with cholangiocarcinoma are therefore candidates for chemotherapy.. In Denmark the combination therapy of Gemcitabine, Oxaliplatin and Capecitabine has been used in recent years. Based on experience with gastrointestinal tumors, however, there seems to be an effect of new biological substances, including EGFR antibodies. There are casuistic reports on the specific effect of a monoclonal antibody against EGFR in cholangiocarcinoma.. The effect of EGF is mediated through an intracellular pathway involving the KRAS protein. It has been shown that a mutation of KRAS causes the EGF system to be constantly activated. Effect in patients with a KRAS mutation is therefore not to be expected. Approximately 50% of the patients present this mutation. ...
Although the incidence of hepatolithiasis is decreasing as the pattern of gallstone disease changes in Asia, the prevalence of hepatolithiasis is persistently high, especially in Far Eastern countries. Hepatolithiasis is an established risk factor for cholangiocarcinoma (CCA), and chronic proliferat …
Find the best cholangiocarcinoma doctors in Kolkata. Get guidance from medical experts to select cholangiocarcinoma specialist in Kolkata from trusted hospitals - credihealth.com
Cholangiocarcinoma is a malignant tumor that originates from the bile duct epithelium (Roberts et al., 1997). Based on its anatomical location in the biliary tree, cholangiocarcinoma is conventionally classified by the World Health Organization as an intrahepatic (ICC) or extrahepatic cholangiocarcinoma (ECC) (Bosman et al., 2010; Patel, 2011). ICC and ECC are biologically distinct, and therefore manifest substantial differences in terms of incidence, mortality, and risk factors (Cardinale et al., 2010). Cholangiocarcinoma has a poor prognosis because it is notoriously difficult to diagnose due to its late clinical presentation, and is refractory to conventional chemotherapy and radiation therapy (Blechacz and Gores, 2008; Blechacz et al., 2011; Khan et al., 2012). Gemcitabine and cisplatin has become the standard regimen for patients with advanced or metastatic cholangiocarcinoma (Ramirez-Merino et al., 2013; Valle et al., 2010). However, response to the combination chemotherapy in ...
[504 Pages Report] Check for Discount on Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016 report by Global Markets Direct. Global Markets Directs, Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review,...
Cholangiocarcinoma (CCA) is the second most common liver cancer and it is associated with a poor prognosis. CCA can be divided into intrahepatic, hilar and distal. Despite the subtype, the median survival is 12-24 months without treatment. Liver transplantation (LT) is worldwide recognized as a curative option for hepatocellular carcinoma. On the other hand, the initial results for LT for CCA were very poor mainly due to a lack of adequate patient selection. In the last two decades, improvement has been made in the management of unresectable hilar CCA, and the results of LT after neoadjuvant chemoradiation have been shown to be promising ...
Expression of MUC1 was detected immunohistochemically in 38 (76%) of 50 cases of m-ICC (ductal type, 18; cytoplasmic type, 20; and negative type, 12). Seventy-five percent of patients with lymph node metastasis had the cytoplasmic type MUC1 expression. Lymph node dissection was performed in only 20 patients, but significant correlation was demonstrated between MUC1 expression and lymph node metastasis (P = 0.0227). The location of MUC1 expression correlated with surgical outcome in m-ICC. Patients with the cytoplasmic type expression showed significantly lower survival rates. Univariate analysis revealed that MUC1 expression was a statistically significant risk factor affecting outcome in m-ICC (P = 0.0028). Furthermore, expression of MUC1 was found to be a statistically significant independent risk factor in multivariate analysis (P = 0.0063). ...
Background: c-MET is a proto-oncogene that encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF). Activation of HGF-c-MET signaling involves cell invasiveness and evokes metastasis through direct involvement of tumor angiogenesis. However, the value of c-MET overexpression is still unknown in metastatic BTC.. Methods: We analyzed the incidence and clinicopathologic characteristics of c-MET overexpression in advanced BTC. Moreover, we investigated the value of c-MET overexpression in predicting response to gemicitabine plus cisplatin (GC), a first line standard regimen, and as a prognostic marker in metastatic BTC.. Results: The BTC subtype distribution (N=44) was as follows: intrahepatic cholangiocarcinoma (IHCC, n=7), extrahepatic cholangiocarcinoma (EHCC, n=25) and gallbladder cancer (GBC, n=12). Liver (52.3%) was the predominant metastatic site, followed by lymph nodes (36.4%) and bone (15.9%). Among the 44 patients analyzed for c-MET expression, 15 (34.1%) exhibited c-MET ...
My mother died of Cholangiocarcinoma. This is a very uncommon cancer of the bile duct. I have since that day, started this site. Not until today did I look up Cholangiocarcinoma specifically. What I just found astounds me... Was Mom taking a trial drug? A drug that wasnt even approved by the FDA? She…
Safety Profile. The most common treatment-related adverse events among all patients who received ivosidenib (including after crossover) included nausea (32.1%), diarrhea (28.8%), fatigue (23.7%), cough (19.2%), abdominal pain (18.6%), ascites (18.6%), decreased appetite (17.3%), anemia (16.0%), and vomiting (16.0%). Grade 3 adverse events were reported in 46% of patients treated with ivosidenib compared to 36% of patients treated with placebo. More of the placebo arm (8.5% vs. 5.8%) discontinued treatment due to toxicity, and ivosidenib was associated with better physical and emotional functioning on quality-of-life measures.. "These pivotal data demonstrate the clinical relevance and benefit of ivosidenib in patients with IDH1-mutated cholangiocarcinoma and establish the role for genomic testing in this rare cancer with a high unmet need," Dr. Abou-Alfa said. All patients with cholangiocarcinoma should be tested for the IDH1 mutation, he maintained.. FIGHT-202. FIGHT-202 was a global, ...
BACKGROUND Intrahepatic cholangiocarcinoma is a rare condition which typically occurs in males between 50 and 70 years of age, and presents with symptoms related to biliary obstruction including jaundice, pruritus, and dark urine. Other common symptoms at presentation include abdominal pain, weight loss, and fever. CASE REPORT We present a case of a 67-year-old female initially presenting with chest pain at rest, found to have a lung nodule on diagnostic imaging at the time of admission. On further imaging, a 9 cm liver lesion was incidentally discovered, initially suspicious for hepatocellular carcinoma on imaging, with initial biopsy staining CK7 positive, and CK20 negative ...
A110 Cholangiocarcinoma (CCA), a malignant tumor of the bile duct epithelium, is one of the major of cancers in Northeast Thailand. This disease is difficult to diagnose and has a high mortality rate, thus posing an important public health problem in this region. Generally, cancer arises from dysregulation of tumor suppressor genes and oncogenes. c-Met, hepatocyte growth factor (HGF) receptor, and its ligand, HGF, regulate diverse biological responses including proliferation, migration and invasion, key features of metastatic cancer. Overexpression of c-Met has frequently been found in cholangiocarcinoma especially of well-differentiated type suggesting the role of c-Met in cholangiocarcinogenesis. In this study the role of HGF in invasiveness of cholangiocarcinoma was investigated using the human CCA cell line, KKU-213, in which c- Met expression is high when compare to immortalized cholangiocyte, H-69. Activation of c-Met by HGF induced KKU-213 cell proliferation, invasion and motility. ...
Histamine regulates functions via four receptors (HRH1, HRH2, HRH3, and HRH4). The d-myo-inositol 1,4,5-trisphosphate (IP3)/Ca2+/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates cholangiocarcinoma growth. We evaluated the role of HRH3 in the regulation of cholangiocarcinoma growth. Expression of HRH3 in intrahepatic and extrahepatic cell lines, normal cholangiocytes, and human tissue arrays was measured. In Mz-ChA-1 cells stimulated with (R)-(α)-(−)-methylhistamine dihydrobromide (RAMH), we measured (a) cell growth, (b) IP3 and cyclic AMP levels, and (c) phosphorylation of PKC and mitogen-activated protein kinase isoforms. Localization of PKCα was visualized by immunofluorescence in cell smears and immunoblotting for PKCα in cytosol and membrane fractions. Following knockdown of PKCα, Mz-ChA-1 cells were stimulated with RAMH before evaluating cell growth and extracellular signal-regulated kinase (ERK)-1/2 phosphorylation. In vivo experiments were done in BALB/c ...
Background: iCCA is the 2nd most common liver malignancy and with a poor patient prognosis. The ABC-02 study established gemcitabine+cisplatin (gem-cis) as the standard of care (SOC) in 1st line (1L) systemic chemotherapy (CT). The objective was to examine the treatment (tx) patterns and time trends in the tx received by patients (pts) with iCCA in the United States before and after ABC-02 study was published. Methods: Retrospective data from the Optum Research Database, which included commercial and Medicare Advantage health plan members between January 1, 2006 and June 30, 2018, were used. Eligible pts were aged ≥ 18 years; had ≥ 2 nondiagnostic claims of primary iCCA diagnosis (International Classification of Disease [ICD]-9: 155.1 or ICD-10: C22.1) in the identification period (July 01, 2006-March 31, 2018); and had 6 months continuous enrollment prior to and ≥ 3 months follow-up (or less due to death) from the date of first diagnosis. Tx patterns in the periods before and after ABC-02 ...
Sigma-Aldrich offers abstracts and full-text articles by [Maiko Terada, Kenichi Horisawa, Shizuka Miura, Yasuo Takashima, Yasuyuki Ohkawa, Sayaka Sekiya, Kanae Matsuda-Ito, Atsushi Suzuki].
This podcast is part of the 2017 NSH Symposium/Convention Poster Podcast Series. The lead author of this poster is Ruth Fidler. For more information on the author and to view the abstract, visit The Block. view more ...
Cholangiocarcinoma, also known as bile duct cancer, is often treated the same way as hepatocellular carcinoma, the most common form of primary liver cancer that develops in the main type of liver cell.
Sigma-Aldrich offers abstracts and full-text articles by [Papavee Samatiwat, Auemduan Prawan, Laddawan Senggunprai, Veerapol Kukongviriyapan].
Learn more about Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®) (Patients) from the National Cancer Institute at Siteman Cancer Center.
Learn about bile duct cancer (cholangiocarcinoma) from the Cleveland Clinic, including information on treatment options, stages & more.
Expression of endoplasmic reticulum oxidoreductase 1-α in cholangiocarcinoma tissues and its effects on the proliferation and migration of cholangiocarcinoma cells
The major objective of this R21 application is to demonstrate the feasibility of using an emerging biophotonics technology - partial-wave spectroscopic microscopy (PWS) for the diagnosis and surveillance of cholangiocarcinoma (CCA). CCA is a primary malignancy in bile duct epithelium. Although it is a rare cancer, the global incidence of this cancer is on the rise. It is a deadly disease with a median survival of months. However, significant improvements in survival rates are possible when the cancer is diagnosed at an early localized stage. Current imaging techniques suffer from either low sensitivity and sometimes lead to significant complications such as pancreatitis and cholangitis. The histopathological confirmation is notoriously difficult, with a suboptimal sensitivity of 9% up to 67% even when the advanced molecular techniques (e.g., fluorescence in situ hybridization (FISH)) were applied. These low rates are in large part due to the challenges of identifying malignant cells with ...
In addition to its well-established role in embryo development, epithelial-to-mesenchymal transition (EMT) has been proposed as a general mechanism favoring tumor metastatization in several epithelial malignancies. Herein, we review the topic of EMT in cholangiocarcinoma (CCA), a primary liver cancer arising from the epithelial cells lining the bile ducts (cholangiocytes) and characterized by an abundant stromal reaction. CCA carries a dismal prognosis, owing to a pronounced invasiveness and scarce therapeutic opportunities. In CCA, several reports indicate that cancer cells acquire a number of EMT biomarkers and functions. These phenotypic changes are likely induced by both autocrine and paracrine signals released in the tumor microenvironment (cytokines, growth factors, morphogens) and intracellular stimuli (microRNAs, oncogenes, tumor suppressor genes) variably associated with specific disease mechanisms, including chronic inflammation and hypoxia. Nevertheless, evidence supporting a complete EMT of
Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Carcinoma, Ductal, Breast; Melanoma; Solid Tumors; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and ...
Discussion This is the first study that demonstrates the effects of glyphosate on cholangiocarcinoma cells, and provides a better understanding of the possible mechanisms related to its effects. The low concentrations of glyphosate tested in this study are relevant to the range of levels that have been reported in the environment and detected in humans (Acquavella et al., 2004; Bai and Ogbourne, 2016; Kongtip et al., 2017). Previous studies have reported that E2 induces cell proliferation in an ERα expressing CCA, HuH28 cell line (Alvaro et al., 2006). It was reported that E2 also induced the expression levels of several proteins, including ERα, VEGF, VEGFR, IGF-1, and IGF-1R, as well as downstream signaling proteins associated to cell proliferation. In this study, we found that 10−11 to 10−5 M of glyphosate and E2 induced cell proliferation in HuCCA-1 cells under estrogen withdrawal conditions and the inductive effects were inhibited by ER antagonists. This study also demonstrated the ...
Hello all,. My father (aged 57) was recently diagnosed with cholangiocarcinoma and they are not sure if it is operable. We have been offered a clinical trial regarding nab-paclitaxel, gemcitabine, and cisplatin. Have any of you had any experiences using this cocktail? Or know any information regarding it? We would love to know your thoughts/opinions before we decide to move forward.. ...
Learn about the TNM System, a standard system for describing the extent of a cancers growth in cases of cancer such as cholangiocarcinoma.
The Cholangiocarcinoma Foundation has created this important education campaign for the benefit of its constituency and the broader community. To that end, the Foundation encourages broad dissemination of these resources and materials. Promotion of the Mutations Matter campaign by third parties does not indicate endorsement by the Foundation of those third parties or any of their programs, activities or products.. ...
Learn more about Cholangiocarcinoma at Reston Hospital Center DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Learn more about Cholangiocarcinoma at Reston Hospital Center DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Magnetic resonance imaging, or MRI, uses a magnet to examine the inside of your body, useful for diagnosing conditions like cholangiocarcinoma.
UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
Most studies looking at the expression of Bcl-2 in cholangiocarcinoma report varying amounts of Bcl-2 protein expression in this disease.24 In contrast, a study looking at Bcl-2 protein expression in cholangiocarcinoma recently reported that none of the cholangiocarcinoma samples examined expressed the Bcl-2 protein.36 With Bcl-2 expression detected in the internal positive controls and in regenerating intrahepatic ductular epithelium, an observation reported previously,37 our inability to detect the of Bcl-2 protein is unlikely to be a result of poor antigen retrieval or low Bcl-2 antibody activity. There have been suggestions that in some cell types a reciprocal expression of survival proteins Bcl-2 and Bcl-XL occurs. Considering there are still many unanswered questions about the cellular control and preference of expression of the different Bcl-2 genes, this might explain the differences in reported findings. It may be that as we learn more about these proteins, reasons for the differences ...
Cholangiocarcinomas (bile duct cancers) arise from the epithelial cells of the bile ducts. Although they are rare in the United States, these cancers are highly lethal because most are locally advanced at presentation. (See.)The clinical manifestatio
bhuiya, Complete Blood Count Abnormal, Weight Loss Symptom Checker: Possible causes include Hepatocellular Carcinoma, Adenocarcinoma of the Colon, Intrahepatic Cholangiocarcinoma. Check the full list of possible causes and conditions now! Talk to our Chatbot to narrow down your search.
KAWAGUCHI Takumi , KAJI Ryohei , HORIUCHI Hiroyuki , SHIRONO Tomotake , ISHIDA Yusuke , OKABE Yoshinobu , ITOU Minoru , MITSUYAMA Keiichi , AKIBA Jun , NAKASHIMA Osamu , YANO Hirohisa , KAGE Masayoshi , HARADA Masaru , SAKISAKA Shotaro , SATA Michio Hepatology research : the official journal of the Japan Society of Hepatology 41(12), 1253-1259, 2011-12-01 Ichushi Web References (20) ...
Background: Cholangiocarcinoma remains to be a challenging case to diagnose and manage as it usually presents in advanced stage and survival rate remains dismal despite the medical breakthroughs. It is usually classified as intrahepatic, perihilar or distal tumor which can lead to bile duct obstruction causing sluggish flow of bile through the biliary tract and promoting increased absorption of bilirubin, bile acids and bile salts into systemic circulation accounting for the occurrence of jaundice, dark-colored urine and generalized pruritus. It usually becomes symptomatic when the tumor has significantly obstructed the biliary drainage causing painless jaundice and deranged liver function with cholestatic pattern. Jaundice occurs in 90% of the cases when the tumor has obstructed the biliary drainage system. A markedly dilated gallbladder as initial presenting feature in the absence of other typical obstructive clinical manifestations of an advanced stage of the cholangiocarcinoma is rare ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
We value your privacy. Your user session will expire in 2 minutes. To stay logged in, please refresh the page or, if you are ...
Liver cancer. Gross clinical specimen of a sectioned human liver with a malignant (cancerous) tumour (neoplasm) of the bile duct. This is a rare cancer known as cholangiocarcinoma or cholangioma, found most often in patients from certain parts of Africa and Asia. Its cause is unknown. Symptoms of cholangiocarcinoma include jaundice & weight loss. - Stock Image M131/0431
The first-line investigation in a patient with jaundice or right upper quadrant pain is ultrasonography (US). Biliary duct dilatation is easily demonstrated with US, but the tumor mass is seldom local... more
Teaching Files with CT Medical Imaging and case studies on Anatomical Regions including Adrenal, Colon, Cardiac, Stomach, Pediatric, Spleen, Vascular, Kidney, Small Bowel, Liver, Chest | CTisus
TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Guest RV, Boulter L, Dwyer BJ, Kendall TJ, Man T-Y, Minnis-Lyons SE, Lu W-Y, Robson AJ, Gonzalez SFerreira, Raven A et al.. 2016. Notch3 drives development and progression of cholangiocarcinoma.Proc Natl Acad Sci U S A. 113(43):12250-12255. ...
Case Scenario Mrs. J., is a woman in her 40s with cholangiocarcinoma*, which is advanced. She has been admitted to the hospital with a new onset of back pain, nausea and vomiting. She has already undergone surgery and a course.
Kanser Saluran Hempedu atau dikenali sebagai Cholangiocarcinoma merupakan kanser yang jarang berlaku dan jarang juga diperkatakan. Hampir 3 peratus daripada kanser yang melibatkan organ dan saluran pemakanan melibatkan kanser saluran hempedu. Ianya melibatkan ketumbuhan yang berlaku pada saluran hempedu samada di dalam
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage ...
Cholangiocarcinomas (CC) frequently demonstrate lymphatic spread. We investigated lymph node (LN) counts after resection of extrahepatic CC and survival based on the SEER 1973-2004 database. Out of 20
Background: Cholangiocarcinoma (CCA) is a serious malignant tumor. Long non-coding RNA NNT-AS1 (NNT-AS1) takes crucial roles in several tumors. So, we planned to research the roles and underlying mechanism of NNT-AS1 in CCA.Results: NNT-AS1 overexpression was appeared in CCA tissues and cell lines. Proliferation was promoted by NNT-AS1 overexpression in CCLP1 and TFK1 cells. Besides, NNT-AS1 overexpression reduced E-cadherin level and raised levels of N-cadherin, vimentin, Snail and Slug. However, the opposite trend was occurred by NNT-AS1 knockdown. Further, NNT-AS1 overexpression promoted phosphatidylinositol 3 kinase (PI3K)/AKT and extracellular signal-regulated kinase (ERK)1/2 pathways. MiR-203 was sponged by NNT-AS1 and miR-203 mimic reversed the above promoting effects of NNT-AS1. Additionally, insulin-like growth factor type 1 receptor (IGF1R) and zinc finger E-box binding homeobox 1 (ZEB1) were two potential targets of miR-203.Conclusion: NNT-AS1 promoted proliferation, EMT and PI3K/AKT and ERK1
Researchers are exploring how broadly liquid biopsies might be used. In the Journal of Clinical Oncology: Precision Oncology, a Mayo Clinic research team reported the array of cancer-related genetic mutations present in liquid biopsies of bile duct cancer, a form of liver cancer also known as cholangiocarcinoma. "We charted the landscape of genetic alterations present in circulating tumor DNA among patients with cholangiocarcinoma," explains Dr. Mody, the articles lead author. The team evaluated liquid biopsies in one of the largest patient cohorts to date: 124 patients with cholangiocarcinoma who were treated across Mayos three campuses. "Our findings provide a foundation for further development of liquid biopsies as a way to advance precision medicine for patients with cholangiocarcinoma," he says.. Cholangiocarcinoma is uncommon in the U.S., where about 5,000 new cases are diagnosed each year, though numbers have been on the rise in recent decades. The cancer is more prevalent in Southeast ...
Cancer of the bile duct (also called cholangiocarcinoma) is extremely rare. The true incidence of bile duct cancer is unknown, however, because establishing an accurate diagnosis is difficult. Traditionally, bile duct tumors located within the liver have been classified with hepatocellular carcinoma as primary liver...
Cholangiocarcinoma (CCA) - bile duct cancer - is associated with late presentation, poses challenges for diagnosis and has high mortality, features that highlig...
Background: The objective of the current study was to assess the impact of serum CA19-9 and CEA and their combination on survival among patients undergoing surgery for intrahepatic cholangiocarcinoma (ICC). Methods: Patients who underwent curative-intent resection of ICC between 1990 and 2016 were identified using a multi-institutional database. Patients were categorized into four groups based on combinations of serum CA19-9 and CEA (low vs. high). Factors associated with 1-year mortality after hepatectomy were examined. Results: Among 588 patients, 5-year OS was considerably better among patients with low CA19-9/low CEA (54.5%) compared with low CA19-9/high CEA (14.6%), high CA19-9/low CEA (10.0%), or high CA19-9/high CEA (0%) (P , 0.001). No difference in 1-year OS existed between patients who had either high CA19-9 (high CA19-9/low CEA: 70.4%) or high CEA levels (low CA19-9/high CEA: 72.5%) (P = 0.92). Although patients with the most favorable tumor marker profile (low CA19-9/low CEA) had the ...
Though much is known about the pathology of the rats liver during chemical carcinogenesis, and the associated biochemical changes have been studied extensively with some compounds, especially 4-dimethylaminoazobenzene (DAB, butter yellow), hardly any attempt has been made to follow such changes progressively or to correlate them with the histological findings. Malignant tumours of the liver are roughly divisible into cancers of the bile duct cells (cholangiocarcinomas) and those of the liver cells (hepatomas). In our experiments cholangiocarcinomas were produced by feeding thioacetamide or DAB, whereas hepatomas resulted if DAB with a vitamin B-rich diet was used. The events which decide the type of tumour which develops may be summarized thus: a cholangiocarcinoma occurs when the following changes are found in the liver, damage to parenchymal cells, proliferation of bile duct tissue, a drop in the mitochondrial fraction, and the phenomenon of ageing of mitochondria. During this time there ...
Bile duct cancer symptoms include jaundice and abdominal pain. Turn to the expert gastroenterologists at Johns Hopkins for accurate diagnosis and personalized treatment.
Looking for simple explanations to difficult medical terms that tend to puzzle you? This glossary can help you to easily understand medical terms related to the article on Bile Duct Cancer
Liver tumors: One of the major areas of my research interest liver tumors. Some of the studies have been collaborative efforts with other academic Institutions in the country, while some have been my own. We have evaluated various markers that can be applied in the diagnostic work-up of hepatocytic masses, including hepatocellular carcinoma (HCC), hepatic adenoma (HA) and focal nodular hyperplasia (FNH) over the years. Our ongoing research in this area is looking at new markers and their diagnostic utility in the work-up of hepatic masses. We are also studying the HCCs that arise in patients with cirrhosis and chronic liver disorders and compare them with those without cirrhosis and known liver disease.. One of my major areas of research interest in liver tumors is Cholangiocarcinoma (CC). It is the second most common primary malignant neoplasm of the liver. The precursor lesions of cholangiocarcinoma are not well understood. Based on observations from clinical cases, we suspect that many of ...
Evidence-based recommendations on endoscopic bipolar radiofrequency ablation for biliary obstruction caused by bile duct and pancreas cancers..
Over the past decade, it has become apparent that the human polybromo-1 protein (BAF180) has a critical role in cancer. BAF180 is known to be a driver mutation in clear cell renal cell carcinoma, where it has been found to be mutated in approximately 40% of cases. Mutations have also been found in several other cancers, including intrahepatic cholangiocarcinomas and epithelioid sarcomas. BAF180 is the chromatin targeting subunit of the PBAF (Polybromo-associated BRG1-associated factor) chromatin remodeling complex, a role facilitated by its nine domains: six bromodomains, which recognize and bind to acetylated lysines on histones; two BAH (bromo-adjacent homology) domains, found to be critical for PCNA ubiquitination following DNA damage; and one HMG (high mobility group) box, the DNA binding component. Furthermore, proper expression of BAF180 has also been linked to cardiac development and cell cycle regulation. Despite these associations, the molecular level interactions of full-length BAF180 have yet
Exome sequencing reveals frequent inactivating mutations in BAP1, ARID1A, and PBRM1 in intrahepatic cholangiocarcinomas. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJA, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, TortoraG, de Braud F, Scarpa A, Jarnagin W, Klimstra D, Karchin R, Velculescu VE, Hruban RH, Vogelstein B, Kinzler KW, Papadopoulos N, Wood LD. Nat Genet. 2013 Dec; 45(12):1470-3 ...
Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016 Dec; 7(6):819-827 ...
Catherine Jane Midgley Sorenson, 1949 - 2011. On December 31, 2011, Cathys courageous fight with cancer ended and she returned home to her Heavenly Father. Cathy was born March 23, 1949 in Salt Lake City, Utah to Frank Park and Nedra Midgley, the sixth of eight children. From an early age, Cathy had a special relationship with her parents and valued family. Some of her fondest childhood memories were visiting her grandparents in California and their visits to Utah. In 1967, Cathy graduated from East High School in Salt Lake City. After some schooling in Chicago, she returned to Salt Lake where she continued to work until she met Jay Parson Sorenson. She and Jay were married on May 20, 1977 and he has been her eternal companion since that time. Cathy and Jay quickly started a family and are parents to five children. Her family, including her husband, five children, their spouses, and her eight grandchildren were the center of her life as she was an amazing wife, mom, grandmother, sister, aunt, ...
Lung scarring can be a highly dangerous condition and is usually caused by inhaling dangerous chemicals or by infections. Lung scarring is generally defined by which area of the lung is injured, with the perihilar area, which is the major entrance for the major veins and arteries of the lungs, being the most common.
Researchers in radiology at Memorial Sloan Kettering continue to assess multiple imaging methods in the quest to improve treatment options and success rates for patients with biliary cancers such as cholangiocarcinoma.
Cell lines and human tissue samples. Cell lines from four human pancreatic carcinomas (SU8686, AsPC1, BxPC3, and CFPAC1), two gastric cancers (AGS and MKN7), three hepatic carcinomas (Alexander, Hep3B, and HepG2), a cholangiocarcinoma (HuCCT), and embryonic kidney (HEK293T) were purchased from the American Type Culture Collection (Manassas, VA) or the Japanese Riken Cell Bank (Tsukuba, Japan). Normal hepatocytes were purchased from Dainippon Pharma (Osaka, Japan) and normal diploid colonocytes (CCD841) were purchased from American Type Culture Collection. Tissue specimens obtained during surgery or endoscopic resection were obtained from the University of Tokyo Hospital (Tokyo, Japan) and Motojima Memorial Hospital (Gumma, Japan) after approval from the medical ethics committee and the acquisition of informed consent. Some samples of colonic cancer and surrounding precancerous tissue were collected from identical specimens. Formalin-fixed, paraffin-embedded sections were examined by H&E staining ...
In cases of biliary stasis, detoxification can be problematic for the client and the therapist, so improving biliary flow should be a consideration. Biliary tract disease is on the increase with cholangiocarcinoma occurring in 65% of cases with recurring symptoms from gallstones in the over-65s. Patients who fall into the "fair, fat, forty and fertile" category are also at increased risk. Alteration ...
The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas. Patients will receive anetumab ravtansine every three weeks in monotherapy for most indications. In cholangiocarinoma and adenocarinoma of the pancreas, 3-weekly anetumab ravtansine is administered in combination with cisplatin or gemcitabine respectively (both administered in a 2 week on / 1 week off schedule). Treatment will continue until disease progression or until another ...
Venturini M, et al. Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: A preliminary study. British Journal of Radiology 89: 20160247, No. 1067, Nov 2016. Available from: URL: http://doi.org/10.1259/bjr.20160247 - Italy ...
Silmitasertib is currently in a Phase 2 randomized trial for cholangiocarcinoma, and has proven to be safe and well-tolerated in human.
Greten T, Ulahannan S, Scheithauer W. Greten T, Ulahannan S, Scheithauer W Greten, Tim, et al.Biliary: Gallbladder Cancer and Cholangiocarcinoma. In: Boyiadzis MM, Frame JN, Kohler DR, Fojo T. Boyiadzis M.M., Frame J.N., Kohler D.R., Fojo T Eds. Michael M. Boyiadzis, et al.eds. Hematology-Oncology Therapy, 2e New York, NY: McGraw-Hill; . http://hemonc.mhmedical.com/content.aspx?bookid=1611§ionid=126320945. Accessed January 22, 2018 ...
The benefit of adjuvant radiotherapy (ART) for extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBC) is unclear, with conflicting results from nonrandomized studies. We reported a meta-analysis to determine the impact of adjuvant radiotherapy on survival. PubMed, EMBASE, Cochrane Library and CNKI databases were searched to identify clinical trials of postoperative ART versus no radiotherapy for EHCC and GBC. The obtained data were analyzed using RevMan 5.3 and Stata 14.0 statistical software. Differences between two groups were estimated by calculating the odds ratio (OR) and 95% confidence interval (CI). A total of 21 clinical trials involving 1465 EHCC and GBC patients were selected according to the inclusion and exclusion criteria and included in this meta-analysis. The meta-analysis showed the following: The 5-year overall survival (OS) rate was higher in the ART group than in the no radiotherapy group (OR = 0.63; 95% CI = 0.50-0.81, p = 0.0002). The 5-year OS rate was significantly
6) Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: TheLiver Cancer Pooling Project. by Petrick JL1, Freedman ND2, Graubard BI2, Sahasrabuddhe VV2, Lai GY3, Alavanja MC2, Beane-Freeman LE2, Boggs DA4, Buring JE5, Chan AT6, Chong DQ7,Fuchs CS8, Gapstur SM9, Gaziano JM10, Giovannucci EL11, Hollenbeck AR12, King LY6, Koshiol J2, Lee IM5, Linet MS2, Palmer JR4, Poynter JN13, Purdue MP14, Robien K15, Schairer C2, Sesso HD5, Sigurdson AJ2, Zeleniuch-Jacquotte A16, Wactawski-Wende J17, Campbell PT9, McGlynn KA2.(PubMed ...
Intrahepatic cholangiocarcinoma (5/7/2018). Bibliography. Peer Reviewed Articles. Toms Augustin, Glass T, James B, Schwartz B. Neighborhood psychosocial hazards and cardiovascular disease: the Baltimore Memory Study. American Journal of Public Health. 2008 Sep;98(9):1664-70. Epub 2008 Jul 16.. Toms Augustin, Siddharth Bhende, Keyur Chavda, Thomas J VanderMeer, Burt Cagir. CT Scans and Acute Appendicitis: A Five-Year Analysis from a Rural Teaching Hospital. Journal of Gastrointestinal Surgery. 2009 Jul;13(7):1306-12. Epub 2009 Apr 21.. 3. Toms Augustin, Thomas J VanderMeer. Intraductal papillary mucinous tumor- a clinicopathological review. Surgical Clinics of North America. 2010 Apr; 90 (2):377-98.. 4. Toms Augustin, Burt Cagir, Thomas VanderMeer. Characteristics of perforated appendicitis in a rural population: Effect of delay is confounded by age and gender J Gastrointest Surg. 2011 Jul;15(7):1223-31. Epub 2011 May 10.. 5. Ali Aminian, Saeed Shoar, Zhamak Khorgami, Toms Augustin, Philip R ...
MeSH-minor] Adenoma, Liver Cell / mortality. Adenoma, Liver Cell / pathology. Adenoma, Liver Cell / surgery. Adrenal Gland Neoplasms / mortality. Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Adult. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Breast Neoplasms / mortality. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Female. Focal Nodular Hyperplasia / mortality. Focal Nodular Hyperplasia / pathology. Focal Nodular Hyperplasia / surgery. Hemangioma / mortality. Hemangioma / pathology. Hemangioma / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / ...
Intrahepatic cholangiocarcinoma (ICC) is a rare cancer of the bile ducts in the liver, with limited treatment options and a poor prognosis. In its advanced stages, only one chemotherapy regimen has been shown to improve survival, but those treated usually dont live more than a year. In 2013, however, researchers at the University of Michigan discovered that a specific kind of genetic alteration in the fibroblast growth factor receptor (FGFR) pathway recurs in patients with bile duct cancer. These so-called FGFR2 "fusions" were subsequently found to have an incidence of about 10% to 20% in ICC-and are now promising therapeutic targets in this disease.. Massachusetts General Hospital Cancer Center was one of the lead sites in a phase II multicenter clinical trial of the selective FGFR inhibitor BGJ-398 in patients with advanced bile duct cancer harboring FGFR alterations. Researchers found that BGJ398 led to significant tumor shrinkage in 22% of the study population, but in many cases, the tumor ...
Northeastern Thailand has the highest levels bile duct cancer in the world. The determination that plasma IL-6 levels are associated with bile duct fibrosis (a precursor state to bile duct cancer) and early bile duct cancer were done by examining participants in the Khon Kaen Cholangiocarcinoma Cohort, the largest cancer cohort of its type in the world, and an NIH sponsored project in collaboration with George Washington University and Khon Kaen University. In this study, researchers visited nearly 4,000 individuals resident in rural areas of Thailand, where the parasite is endemic to conduct ultrasound studies to detect advanced bile duct fibrosis and early bile duct cancer and then link the ultrasound results with levels of plasma IL-6. This research was done in collaboration with Drs. Banchob Sripa, Bandit Thinkhamrop, Eimorn Mairiang, and Thewarach Laha from the Khon Kaen University School of Medicine and School of Public Health. ...
TY - JOUR. T1 - Clinical features and management of primary sclerosing cholangitis. AU - Silveira, Marina G.. AU - Lindor, Keith. PY - 2008. Y1 - 2008. N2 - Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts, resulting in cirrhosis and need for liver transplantation and reduced life expectancy. The majority of cases occur in young and middle-aged men, often in association with inflammatory bowel disease. The etiology of primary sclerosing cholangitis includes immune-mediated components and elements of undefined nature. No effective medical therapy has been identified. The multiple complications of primary sclerosing cholangitis include metabolic bone disease, dominant strictures, bacterial cholangitis, and malignancy, particularly cholangiocarcinoma, which is the most lethal complication of primary sclerosing cholangitis. Liver transplantation is currently the only life-extending therapeutic alternative for patients ...
TY - JOUR. T1 - Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma. AU - Batmunkh, Enkhjargal. AU - Tátrai, Péter. AU - Szabó, Erzsébet. AU - Lódi, Csaba. AU - Holczbauer, Ágnes. AU - Páska, Csilla. AU - Kupcsulik, Péter. AU - Kiss, András. AU - Schaff, Zsuzsa. AU - Kovalszky, Ilona. PY - 2007/10/1. Y1 - 2007/10/1. N2 - Heparan sulfate proteoglycans mediate cell adhesion and control the activities of numerous growth and motility factors. They play a critical role in carcinogenesis and tumor progression. Agrin is a large multidomain heparan sulfate proteoglycan associated with basement membranes in several tissues. The expression of agrin in the liver has recently been described under physiologic and pathologic conditions. However, little is known about its role in malignancies. We aimed to study the mRNA and protein expression of agrin in cholangiocarcinoma (CC) and focused on the differences ...
TY - JOUR. T1 - Primary sclerosing cholangitis and pregnancy. AU - Landon, M. B.. AU - Soloway, R. D.. AU - Freedman, L. J.. AU - Gabbe, S. G.. PY - 1987. Y1 - 1987. N2 - Primary sclerosing cholangitis is a chronic, fibrosing, inflammatory disorder of unknown etiology affecting the biliary tree. We describe a case of a pregnancy complicated by this condition. Remarkably, maternal cholestasis improved with advancing gestation. Despite a marked elevation of bile acid levels in cord blood, the patient was delivered of a healthy term infant. The principles of management and potential effects of primary sclerosing cholangitis on pregnancy care are discussed.. AB - Primary sclerosing cholangitis is a chronic, fibrosing, inflammatory disorder of unknown etiology affecting the biliary tree. We describe a case of a pregnancy complicated by this condition. Remarkably, maternal cholestasis improved with advancing gestation. Despite a marked elevation of bile acid levels in cord blood, the patient was ...
Previous molecular genetic analyses indicate that Opisthorchis viverrini is a complex of at least 2 cryptic species in Thailand and the Lao Peoples Democratic Republic (PDR). Opisthorchis viverrini sensu lato (s.l.) populations can be divided into 6 genetic groups, which correlate with 5 different river wetlands systems. The present study examines the infectivity, growth, fecundity, and body size of O. viverrini s.l. isolates from these systems. Worm recovery was lowest in the Songkhram River, which differed significantly from all other wetland systems. In addition, the Chi River and Nam Ngum River populations also differed significantly. A similar pattern was found for fecundity. These results support the genetic/molecular data indicating a subdivision of O. viverrini populations on the basis of watershed and that propose the existence of cryptic species in Thailand and the Lao PDR. © American Society of Parasitologists ...
Cholangiocarcinoma 2009-06-08 Coeliac disease 2008-05-18 Dengue fever 2011-08-05 ...
Cancers of the biliary tree, including cholangiocarcinoma. Colorectal cancer is a disease of old age: It typically originates ...
"Paraneoplastic porphyria cutanea tarda associated with cholangiocarcinoma: Case report". The Turkish Journal of ...
Text is available under the Creative Commons Attribution/Share-Alike License and the GFDL; additional terms may apply. See Terms of Use for details ...
In 2007, Michael died of cholangiocarcinoma; Craighead was one of the founders of the Cholangiocarcinoma Foundation, serving on ... "Board of Directors". Cholangiocarcinoma Foundation. Retrieved March 3, 2015. "Joni Craighead to Run for Nebraska Legislature, ...
Rustagi T, Dasanu CA (2012). "Risk Factors for Gallbladder Cancer and Cholangiocarcinoma: Similarities, Differences and Updates ... "Liver fluke induces cholangiocarcinoma". PLoS Medicine. 4 (7): 1148-1155. doi:10.1371/journal.pmed.0040201. PMC 1913093 . PMID ...
Ben-Menachem T (August 2007). "Risk factors for cholangiocarcinoma". Eur J Gastroenterol Hepatol. 19 (8): 615-7. doi:10.1097/ ...
For instance, cholangiocarcinomas represent 15% of primary liver cancer worldwide, but in Thailand's Khon Kaen region, this ... Of all cancers worldwide from 2002, 0.02% were cholangiocarcinoma caused by Opisthorchis viverrini. The cancer of the bile ... Currently, there is no effective chemotherapy to combat cholangiocarcinoma, such that intervention strategies need to rely on ... These conditions predispose to cholangiocarcinoma, possibly through an enhanced susceptibility of DNA to damage by carcinogens ...
O. viverrini infection also predisposes the infected for cholangiocarcinoma, a cancer of the bile ducts. A small leaf-like ... In rare cases, cholangitis, cholecystitis, and cholangiocarcinoma can also develop. In humans,O. viverrini inhabits mainly the ... 2016). "Helicobacter Species are Possible Risk Factors of Cholangiocarcinoma". Asian Pacific Journal of Cancer Prevention : ... cholangiocarcinoma (CCA) in the world. About 9.6% of the total population of Thailand is estimated to be infected. It is most ...
It is believed to be a cause of cholangiocarcinoma via liver fluke transmission. Koi hoi is a variety containing raw snail meat ... "Liver Fluke Induces Cholangiocarcinoma". PLoS Medicine. 4 (7): e201. doi:10.1371/journal.pmed.0040201. PMC 1913093 . PMID ...
Resection is an option in cholangiocarcinoma, but less than 30% of cases of cholangiocarcinoma are resectable at diagnosis. ... 60% of cholangiocarcinomas form in the perihilar region and photodynamic therapy can be used to improve quality of life and ... HBV infection is also linked to cholangiocarcinoma. The role of viruses other than HCV or HBV in liver cancer is much less ... Cholangiocarcinoma also has a significant geographical distribution, with Thailand showing the highest rates worldwide due to ...
It is commonly used off-label to treat cholangiocarcinoma and other biliary tract cancers. It is given by injection into a vein ... Plentz, RR; Malek, NP (December 2016). "Systemic Therapy of Cholangiocarcinoma". Visceral Medicine. 32 (6): 427-430. doi: ...
Development of cholangiocarcinoma is progressive. Infection is detected mainly on identification of eggs by microscopic ... cholangiocarcinoma (CCA), and hepatic carcinoma. It is the most prevalent human trematode in Asia, and is still transmitted in ... as a human biological agent of cholangiocarcinoma: a brief review". BMB reports. 49 (11): 590-597. doi:10.5483/BMBRep.2016.49. ... epithelial hyperplasia and sometimes even cholangiocarcinoma, the incidence of which is raised in fluke-infested areas. One ...
High levels of alpha-fetoprotein (AFP) in the blood can be found in many cases of HCC and intrahepatic cholangiocarcinoma. ... Cholangiocarcinoma can be detected with these commonly used tumor markers: carbohydrate antigen 19-9 (CA 19-9), ... More rare primary forms of liver cancer include cholangiocarcinoma, mixed tumors, sarcoma and hepatoblastoma; a rare malignant ... "Serum markers of intrahepatic cholangiocarcinoma". Disease markers. 34 (4): 219-28. doi:10.3233/DMA-130964. PMC 3809974 . PMID ...
Cholangiocarcinoma or bile duct cancer is a form of cancer that is composed of mutated epithelial cells (or cells showing ... Cholangiocarcinoma is considered to be an incurable and rapidly lethal cancer unless both the primary tumor and any metastases ... The Cholangiocarcinoma Foundation The Johns Hopkins Gall Bladder & Bile Duct Cancer Web page Bile Ducts at the US National ... cholangiocarcinoma, cancer of the bile ducts; blockage by a stone in patients with gallstones; and from scarring after injury ...
"World Cholangiocarcinoma Day 2018 CCA: The statistics". worldcholangiocarcinomaday.org. Retrieved 25 January 2018. Sripa, ...
Cholangiocarcinoma, or cancer of the bile duct, is an indication for the Whipple procedure when the cancer is present in the ... Depending on the location and extension of the cholangiocarcinoma, curative surgical resection may require hepatectomy, or ... "Advances in the surgical treatment of hilar cholangiocarcinoma". Expert Review of Gastroenterology & Hepatology. 9 (3): 369-374 ...
Chronically, complications include cholangiocarcinoma and intraductal papillary neoplasm. In RPC the gallstones found within ... "Radiologic spectrum of cholangiocarcinoma: emphasis on unusual manifestations and differential diagnoses". Radiographics: A ... and eventually secondary biliary cirrhosis and cholangiocarcinoma. Suppurative cholangitis, liver abscess, empyema of the ...
Causes can include pancreatitis, cirrhosis, diverticulitis, and cholangiocarcinoma. It is also a known complication of ...
Human cholangiocarcinoma miR-26a promotes cholangiocarcinoma growth by inhibition of GSK-3β and subsequent activation of β- ... Human cholangiocarcinoma tissues and cell lines have increased levels of miR-26a compared with the noncancerous biliary ... On the contrary, miR-26a is overexpressed in high-grade glioma and cholangiocarcinoma. Elevated expression of miR-26b has been ... Zhang J, Han C, Wu T (2012). "MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin". Gastroenterology. 143 ( ...
A Klatskin tumor (or hilar cholangiocarcinoma) is a cholangiocarcinoma (cancer of the biliary tree) occurring at the confluence ... The cause of cholangiocarcinoma has not been clearly defined. A number of pathologic conditions, however, resulting in either ... Cholangiocarcinoma accounts for approximately 2% of all cancer diagnoses, with an overall incidence of 1.2/100,000 individuals ... 52 (1): 1-3. PMC 2595709 . VIDEO - Hilar Cholangiocarcinoma, Klatskin Tumor presented by Fumito Ito, MD, PhD at the University ...
... cholangiocarcinoma). Opisthorchiasis is particularly the leading cause of cholangiocarcinoma in Thailand and the Lao People's ... as a human biological agent of cholangiocarcinoma: a brief review". BMB reports. 49 (11): 590-597. doi:10.5483/BMBRep.2016.49. ... "Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos". Acta Tropica. 120 (Suppl): S158-S168. doi ...
Anton Balasingham, 69, Sri Lankan LTTE senior negotiator, cholangiocarcinoma. John Bridge, 91, British recipient of the George ...
Other causes include strictures of the common bile duct, biliary atresia, cholangiocarcinoma, pancreatitis, cholestasis of ...
"PGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression". Tumour Biology. 35 (8): 8051-64. doi: ...
He died of cholangiocarcinoma (bile duct cancer) in Lymington, Hampshire. In 1955 Pirie won the BBC Sports Personality of the ...
keywords = "Cholangiocarcinoma, Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Hepatocellular carcinoma ... Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Outcome after liver transplantation. Digestive Diseases ... Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma : Outcome after liver transplantation. In: Digestive ... Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Outcome after liver transplantation. Kishore Maganty, ...
Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010;101:579-85.View ArticlePubMedGoogle ... The global epidemiology of clonorchiasis and its relation with cholangiocarcinoma. Infect Dis Poverty. 2012;1:4.View Article ... cholecystitis and cholangiocarcinoma [5, 8]. Clonorchis sinensis was re-classified as a group 1 carcinogen by the International ... Agency for Research on Cancer (IARC) in 2009 [9, 10]. Nearly 5000 new cholangiocarcinoma cases attributed to C. sinensis ...
Adults with cysts are especially predisposed to the development of cholangiocarcinoma, with the occurrence increasing from 0.7 ...
cellular proliferation; cholangiocarcinoma; granulin; liver fluke; O. viverrini; RNA interference. Funders:. Higher Education ... or human cholangiocarcinoma (KKU-M214) cell lines retarded cell hyper-proliferation by 25% and 92%, respectively. Intriguingly ...
Choi B.I., Han J.K., Hong S.T., Lee K.H. 2004: Clonorchiasis and cholangiocarcinoma: etiologic relationship and imaging ...
Cholangiocarcinoma (CCA) is a rare cancerous (malignant) growth in one of the ducts that carries bile from the liver to the ... Cholangiocarcinoma (CCA) is a rare cancerous (malignant) growth in one of the ducts that carries bile from the liver to the ... Intrahepatic cholangiocarcinoma. In: Jarnagin WR, ed. Blumgarts Surgery of the Liver, Biliary Tract and Pancreas. 6th ed. ... Bile duct cancer (cholangiocarcinoma) treatment (PDQ) - health professional version. www.cancer.gov/types/liver/hp/bile-duct- ...
Bile Duct Cancer (Cholangiocarcinoma) (American Society of Clinical Oncology) * General Information about Extrahepatic Bile ... Bile Duct (Cholangiocarcinoma) Cancer: Radiation Therapy (American Cancer Society) * Endoscopic retrograde cholangio ... Surgery for Bile Duct (Cholangiocarcinoma) Cancer (American Cancer Society) * Treatment Option Overview (Extrahepatic Bile Duct ... Article: Primary Liver Cancers: Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. * Article: Identification of ...
AMMF is the UKs only cholangiocarcinoma charity. Our main aims are to raise the awareness of cholangiocarcinoma (bile duct ... AMMF is the UKs only cholangiocarcinoma charity. Our main aims are to raise the awareness of cholangiocarcinoma (bile duct ... AMMF Cholangiocarcinoma Awareness Month 2019. Thank you for taking the time to visit AMMFs 2019 Awareness Month JustGiving ... Each day throughout February, AMMF are encouraging all our supporters to raise awareness of cholangiocarcinoma and also raise ...
... of our study was to evaluate the imaging features and patterns of contrast enhancement in peripheral cholangiocarcinomas with ... Methods: We reviewed the CT scans of 24 patients with 25 peripheral cholangiocarcinomas proved by orthotopic liver ... and contrast enhancement on delayed images are highly suggestive of peripheral intrahepatic cholangiocarcinoma. ... of our study was to evaluate the imaging features and patterns of contrast enhancement in peripheral cholangiocarcinomas with ...
Mutational landscape of intrahepatic cholangiocarcinoma.. Zou S1, Li J2, Zhou H1, Frech C3, Jiang X1, Chu JS4, Zhao X3, Li Y1, ... Intrahepatic cholangiocarcinoma (ICC) is a fatal primary liver cancer (PLC) that affects 5-10% of all PLCs. Here we sequence ...
Cholangiocarcinoma staging is a process used by physicians to describe bile duct cancer in standardized terms regarding the ... Most cholangiocarcinoma staging systems use a numerical scale ranging from 1 through 4, with higher numbers corresponding to ... If youd like to learn more about cholangiocarcinoma staging, the bile cancer experts at Moffitt can explain the statistics and ... The most widely used system is the American Joint Committee on Cancer (AJCC) TNM system, which bases the cholangiocarcinoma ...
For these reasons, cholangiocarcinoma is usually found only after the cancer has advanced enough to cause symptoms. In the ... Cholangiocarcinoma screening cannot be performed with any degree of reliability in individuals who are not experiencing ... If you have questions about cholangiocarcinoma screening and early detection, contact the experts at Moffitt by calling 1-888- ... Because there is currently no cholangiocarcinoma screening method recommended for routine use in the general population, early ...
cholangiocarcinoma synonyms, cholangiocarcinoma pronunciation, cholangiocarcinoma translation, English dictionary definition of ... cholangiocarcinoma. Translations. English: cholangiocarcinoma n colangiocarcinoma m. Spanish / Español: n colangiocarcinoma m. ... In adults the most common tumor was HCC (47%) followed by cholangiocarcinoma (11.7%) and metastatic disease in one patient from ... Devkota was diagnosed Bile Duct Cancer Cholangiocarcinoma at the London-based Kings College Hospital.. Dr Devkota passes away ...
Cholangiocarcinomas (bile duct cancers) arise from the epithelial cells of the bile ducts. Although they are rare in the United ... Intrahepatic cholangiocarcinomas can originate from either small intrahepatic ductules (peripheral cholangiocarcinomas) or ... See Epidemiology, pathogenesis, and classification of cholangiocarcinoma and Treatment of localized cholangiocarcinoma: ... Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using ...
... Muharrem Battal,1 Bünyamin Gürbulak,2 Ozgür Bostanci,1 ... Malignant hypercalcemia and thrombocytopenia may result from bone metastasis of cholangiocarcinoma (CC). Our case was 53-year- ...
... particularly nitrative and oxidative DNA damage and the clinical manifestations of cholangiocarcinoma. ... Lim JH (2003) Cholangiocarcinoma: Morphologic classification according to growth pattern and imaging findings. AJR Am J ... Sirica AE (2005) Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy. Hepatology 41: 5-15. * ... Anderson CD, Pinson CW, Berlin J, Chari RS (2004) Diagnosis and treatment of cholangiocarcinoma. Oncologist 9: 43-57. * View ...
Age-standardized mortality rates from intrahepatic (IC) and extrahepatic (EC) cholangiocarcinoma for men and women, by country. ... Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.[2] Symptoms of ... Darwin PE, Kennedy A. Cholangiocarcinoma at eMedicine *^ Zervos EE, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A, ... Cholangiocarcinoma is rare in the Western world, with estimates of it occurring in 0.5-2 people per 100,000 per year.[1][6] ...
Bile duct carcinoma (cholangiocarcinoma) is a cancer of the bile ducts, the tubes that connect the liver and gall bladder to ...
Does intrahepatic cholangiocarcinoma have better prognosis compared to perihilar cholangiocarcinoma?. J Surg Oncol. 2010 Feb 1 ... Drugs & Diseases , Radiology , Cholangiocarcinoma Imaging Q&A Which imaging modalities are used in the workup of ... Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr. 1997 Jan-Feb. 21(1):59- ... Olthof SC, Othman A, Clasen S, Schraml C, Nikolaou K, Bongers M. Imaging of Cholangiocarcinoma. Visc Med. 2016 Dec. 32 (6):402- ...
Cholangiocarcinoma is the second most frequent primary neoplasm of the liver and its incidence is increasing in Western ... tract and can be categorized according to their anatomical location as intrahepatic and extrahepatic cholangiocarcinomas. The ... Cholangiocarcinoma is the second most frequent primary neoplasm of the liver and its incidence is increasing in Western ... This book contains an up-to-date review of diagnostic and staging tools of cholangiocarcinoma, and of long-term outcome of ...
Workflow of the Cholangiocarcinoma Screening and Car Program (CASCAP). CCA = cholangiocarcinoma, U/S = ultrasonography, CT = ... Cohort profile: cholangiocarcinoma screening and care program (CASCAP).. Khuntikeo N1,2, Chamadol N3,4, Yongvanit P3,5, Loilome ... Cholangiocarcinoma Screening and Care Program (CASCAP), Khon Kaen University, Khon Kaen, 40002, Thailand. [email protected] 12 ... The Cholangiocarcinoma Screening and Care Program (CASCAP) is a prospective cohort study comprising two cohorts- the screening ...
However, most people with cholangiocarcinoma have no identifiable risk factors. Cholangiocarcinoma is considered to be an ... Cholangiocarcinoma, also known as bile duct cancer, is a form of cancer that is composed of mutated epithelial cells (or cells ... A cholangiocarcinoma occurring at the junction where the left and right hepatic ducts meet to form the common hepatic duct may ... Cholangiocarcinoma can affect any area of the bile ducts, either within or outside the liver. Tumors occurring in the bile ...
A biopsy confirmed that she had intrahepatic cholangiocarcinoma, more commonly known as bile duct cancer. ... Tags: Bile, Bile Duct Cancer, Biopsy, Cancer, Carcinoma, Chemotherapy, Cholangiocarcinoma, Cirrhosis, Clinical Trial, CT, CT ... Study offers new hope for patients with intrahepatic cholangiocarcinoma. *Download PDF Copy ... Ghobrial said most patients with intrahepatic cholangiocarcinoma were found to have this type of cancer only after they ...
See a list of publications on cholangiocarcinoma by Mayo Clinic doctors on PubMed, a service of the National Library of ... Researchers at Mayo Clinic are studying new ways to diagnose and treat cholangiocarcinoma. This research is conducted as part ...
See a list of publications on cholangiocarcinoma by Mayo Clinic doctors on PubMed, a service of the National Library of ... Researchers at Mayo Clinic are studying new ways to diagnose and treat cholangiocarcinoma. This research is conducted as part ... Anal cancer, Cholangiocarcinoma, Colon cancer, Esophageal cancer, Hepatocellular carcinoma, Liver cancer, Pancreatic cancer, ... Kidney transplant, Liver transplant, Living-donor transplant, Pancreas transplant, Cholangiocarcinoma, Gallbladder cancer, ...
  • Co-culture of Ov-grn-1 suppressed flukes with human cholangiocyte (H-69) or human cholangiocarcinoma (KKU-M214) cell lines retarded cell hyper-proliferation by 25% and 92%, respectively. (edu.au)
  • See 'Epidemiology, pathogenesis, and classification of cholangiocarcinoma' and 'Treatment of localized cholangiocarcinoma: Adjuvant and neoadjuvant therapy and prognosis' and 'Treatment options for locally advanced cholangiocarcinoma' and 'Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis' and 'Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging' . (uptodate.com)
  • See 'Epidemiology, pathogenesis, and classification of cholangiocarcinoma' . (uptodate.com)
  • Establish ground-level truth on cholangiocarcinoma epidemiology to help drive additional research and therapies. (businesswire.com)
  • Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. (spandidos-publications.com)
  • Bardeesy presented the information during the 2018 Cholangiocarcinoma Foundation Annual Conference, held Jan. 31 through Feb. 2 in Salt Lake City. (curetoday.com)
  • SALT LAKE CITY, UT, USA, August 3, 2018 / EINPresswire.com / -- The Cholangiocarcinoma Foundation recently announced a first of its kind $60,000 collaborative Young Investigator Award with three partner organizations, AMMF - The Cholangiocarcinoma Charity (UK), The Bili Project Foundation, and Target Cancer Foundation. (einpresswire.com)
  • Epidemiologic studies have suggested that the lifetime risk of developing cholangiocarcinoma for a person with PSC is on the order of 10-15%, although autopsy series have found rates as high as 30% in this population. (wikipedia.org)
  • Congenital liver abnormalities, such as Caroli's syndrome (a specific type of five recognized choledochal cysts), have been associated with an approximately 15% lifetime risk of developing cholangiocarcinoma. (wikipedia.org)
  • While this information is an important consideration in planning a patient's treatment, cholangiocarcinoma staging is too general to reliably predict any patient's outcome. (moffitt.org)
  • As part of the cholangiocarcinoma staging process at Moffitt Cancer Center, each patient is thoroughly evaluated by a multispecialty team of bile duct cancer experts, including surgeons, oncologists and other medical professionals. (moffitt.org)
  • If you'd like to learn more about cholangiocarcinoma staging, the bile cancer experts at Moffitt can explain the statistics and put this information into perspective for you. (moffitt.org)
  • Staging of intrahepatic cholangiocarcinoma. (medscape.com)
  • Positron emission tomography/CT (PET/CT) is useful in staging and identify metastasis in intrahepatic cholangiocarcinoma. (appliedradiology.com)
  • Staging depends on the growth pattern/type of cholangiocarcinoma. (radiopaedia.org)
  • Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma ", Hepatology, 2014, 59, 1427-1434. (thefreedictionary.com)
  • Why choose Johns Hopkins Division of Gastroenterology and Hepatology for cholangiocarcinoma? (hopkinsmedicine.org)
  • Histologically or cytologically confirmed cholangiocarcinoma. (swedish.org)
  • Subjects are required to have a histologically-confirmed diagnosis of IDH1 gene-mutated cholangiocarcinoma that is not eligible for curative resection, transplantation, or ablative therapies prior to enrollment.IDH1 mutation testing will be performed at participating investigative sites. (clinicaltrials.gov)
  • Histologically, cholangiocarcinomas are divided into well, moderately and poorly differentiated adenocarcinomas 2 . (radiopaedia.org)
  • Cholangiocarcinoma is a relatively rare neoplasm that is classified as an adenocarcinoma (a cancer that forms glands or secretes significant amounts of mucins). (wikipedia.org)
  • Cholangiocarcinoma is the second most frequent primary neoplasm of the liver and its incidence is increasing in Western countries. (springer.com)
  • The present studies are sought to identify molecular targets that promote Fas-induced apoptosis independent of Fas expression of cholangiocarcinoma. (aacrjournals.org)
  • Our results provided important insights into the identification of potential therapeutical molecular targets for cholangiocarcinoma. (aacrjournals.org)
  • Address correspondence to Kesara Na-Bangchang, Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University, Rangsit Center, Pathum Thani 12120, Thailand. (ajtmh.org)
  • This review summarises the evidence behind reported risk factors and current understanding of the molecular pathogenesis of cholangiocarcinoma, with a focus on inflammation and cholestasis as the driving forces in cholangiocarcinoma development. (biomedcentral.com)
  • An understanding of the molecular pathogenesis of cholangiocarcinoma is vital when developing new diagnostic biomarkers and targeted therapies for this disease. (biomedcentral.com)
  • Our main aims are to raise the awareness of cholangiocarcinoma (bile duct cancer), to provide information, and to support specialised research teams in their work to find the causes, methods of earlier diagnosis and treatments for this disease. (justgiving.com)
  • Cholangiocarcinoma is recognized by the FDA as an orphan disease, usually defined as a condition that affects fewer than 200,000 people nationwide. (news-medical.net)
  • A new understanding of the genetic mutations that drive the rare and difficult-to-treat cancer cholangiocarcinoma, along with the testing of targeted drugs and immunotherapies in people with the disease, are laying the groundwork for long-awaited advances in therapy. (curetoday.com)
  • Cholangiocarcinoma is a heterogeneous and target-rich disease with differences in actionable targets. (nature.com)
  • The agreement allows the Cholangiocarcinoma Foundation to access previously inaccessible information, data, and disease-treatment reference points through Komodo Health's largest, most actionable healthcare map in the U.S. (businesswire.com)
  • Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. (springer.com)
  • Intrahepatic cholangiocarcinoma is a complex disease with three different histologic subtypes, the large duct, small duct, and bile ductular types. (bioportfolio.com)
  • For these reasons, screening is not currently recommended for people at average risk, although it may be considered in people at high risk, such as people with primary sclerosing cholangitis, a chronic liver disease that puts people at high risk for cholangiocarcinoma. (heraldtribune.com)
  • As a rare and lethal disease, cholangiocarcinoma lacks attention and sufficient resources. (einpresswire.com)
  • There is a vast, unmet need for education about cholangiocarcinoma across the entire disease spectrum-from bench to bedside. (einpresswire.com)
  • The current Lancet has a review of cholangiocarcinoma , unfortunately an over-represented disease for us in palliative care. (pallimed.org)
  • Intrahepatic cholangiocarcinoma, a disease with growing incidence for yet unknown reasons, harbors FGFR2 translocations in up to 16% of cases ( 1, 2 ). (aacrjournals.org)
  • Although most people present without any known risk factors evident, a number of risk factors for the development of cholangiocarcinoma have been described. (wikipedia.org)
  • However, most people with cholangiocarcinoma have no identifiable risk factors. (wikipedia.org)
  • Other risk factors for cholangiocarcinoma are mostly beyond a person's control: other liver diseases, parasites and genetic conditions. (heraldtribune.com)
  • A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. (springer.com)
  • To identify possible risk factors and their synergism for cholangiocarcinoma development. (wjgnet.com)
  • Regardless of aetiology, most risk factors for cholangiocarcinoma cause chronic inflammation and/or cholestasis, leading to the activation of common intracellular pathways that result in reactive cell proliferation, genetic/epigenetic mutations and cholangiocarcinogenesis. (biomedcentral.com)
  • Currently NHS England does not routinely fund this treatment for cholangiocarcinoma , based on clinical advice that there is not yet sufficient evidence of its effectiveness compared to other treatments available. (thefreedictionary.com)
  • Intrahepatic and extrahepatic types of cholangiocarcinoma differ significantly in clinical presentation and underlying genetic aberrations. (nature.com)
  • New data from two clinical trials presented at the International Liver Congress 2013 demonstrated substantial improvements in the detection of both HCC and cholangiocarcinoma using diagnostic urine tests. (oncologynurseadvisor.com)
  • Goyal and colleagues ( 6 ) demonstrate that FGFR2 translocations in intrahepatic cholangiocarcinoma are classic oncogene drivers, with response to FGFR inhibition in the clinic followed by development of common gatekeeper mutations in FGFR2 resulting in clinical resistance. (aacrjournals.org)
  • Blood tests of liver function in people with cholangiocarcinoma often reveal a so-called "obstructive picture", with elevated bilirubin , alkaline phosphatase , and gamma glutamyl transferase levels, and relatively normal transaminase levels. (wikipedia.org)
  • Symptoms of cholangiocarcinoma may include abdominal pain , yellowish skin , weight loss , generalized itching , and fever. (wikipedia.org)